Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

This strategic play will take time to pay off, but it could keep growth going. On Sept. 16 Novo Nordisk (NVO 0.04%) and Korro Bio (KRRO -1.45%) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most would assume to be Moderna's (MRNA -2.96%) home territory. It's natural for investors to wonder if the competitive landscape in biopharma may have changed in a big way. And it might -- but probably not in the way that some are expecting. ...